ATE254927T1 - Antagonisten der endothelinwirkung - Google Patents

Antagonisten der endothelinwirkung

Info

Publication number: ATE254927T1
Authority: AT; Austria
Prior art keywords: endothelin; antagonists; treatment; endothelial action; administration
Prior art date: 1996-03-13

Application number

AT97906058T

Other languages

English (en)

Inventor

James D Banting

Jeremy P W Heaton

Michael A Adams

Original Assignee

Univ Kingston

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-13

Filing date

1997-03-13

Publication date

2003-12-15

1997-03-13 Application filed by Univ Kingston filed Critical Univ Kingston

2003-12-15 Application granted granted Critical

2003-12-15 Publication of ATE254927T1 publication Critical patent/ATE254927T1/de

Links

239000005557 antagonist Substances 0.000 title 1
230000003511 endothelial effect Effects 0.000 title 1
102000002045 Endothelin Human genes 0.000 abstract 2
108050009340 Endothelin Proteins 0.000 abstract 2
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract 2
208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
102000008299 Nitric Oxide Synthase Human genes 0.000 abstract 1
108010021487 Nitric Oxide Synthase Proteins 0.000 abstract 1
206010047139 Vasoconstriction Diseases 0.000 abstract 1
230000001154 acute effect Effects 0.000 abstract 1
230000000903 blocking effect Effects 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000002308 endothelin receptor antagonist Substances 0.000 abstract 1
201000001881 impotence Diseases 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
230000035790 physiological processes and functions Effects 0.000 abstract 1
230000025033 vasoconstriction Effects 0.000 abstract 1
230000024883 vasodilation Effects 0.000 abstract 1
229940124549 vasodilator Drugs 0.000 abstract 1
239000003071 vasodilator agent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gynecology & Obstetrics (AREA)
Heart & Thoracic Surgery (AREA)
Reproductive Health (AREA)
Cardiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

AT97906058T 1996-03-13 1997-03-13 Antagonisten der endothelinwirkung ATE254927T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/615,659 US5688499A (en)	1996-03-13	1996-03-13	Antagonism of endothelin actions
PCT/CA1997/000169 WO1997033608A2 (en)	1996-03-13	1997-03-13	Antagonism of endothelin actions

Publications (1)

Publication Number	Publication Date
ATE254927T1 true ATE254927T1 (de)	2003-12-15

Family

ID=24466313

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97906058T ATE254927T1 (de)	1996-03-13	1997-03-13	Antagonisten der endothelinwirkung

Country Status (8)

Country	Link
US (4)	US5688499A (de)
EP (1)	EP0888123B1 (de)
JP (1)	JP2001500840A (de)
AT (1)	ATE254927T1 (de)
AU (1)	AU723384B2 (de)
CA (1)	CA2248047C (de)
DE (1)	DE69726414D1 (de)
WO (1)	WO1997033608A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5688499A (en) *	1996-03-13	1997-11-18	Queen's University At Kingston	Antagonism of endothelin actions
DE19652374A1 (de) *	1996-12-04	1998-06-10	Schering Ag	Verwendung von Endothelin-Konjugaten in der Therapie, neue Endothelin-Konjugate, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
GR1002847B (el)	1997-05-06	1998-01-27		Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
AU756136B2 (en) *	1997-06-23	2003-01-02	Queen's University At Kingston	Microdose therapy
US6268388B1 (en)	1997-08-22	2001-07-31	Bristol-Myers Squibb Company	Method for preventing or treating erectile dysfunction by administering an endothelin antagonist
GR1003199B (el)	1998-08-14	1999-09-01		Χρηση της μισοπροστολης ή και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση της σεξουαλικης δυσλειτουργιας στις γυναικες
US20040063719A1 (en) *	1998-08-26	2004-04-01	Queen's University At Kingston	Combination therapy using antihypertensive agents and endothelin antagonists
CA2340206A1 (en) *	1998-08-26	2000-03-09	Queen's University At Kingston	Use of anti-pressor agents for vascular remodeling in genital dysfunction
US6291471B1 (en)	1998-12-17	2001-09-18	Abb Holdings, Inc.	Use of apomorphine for the treatment of organic erectile dysfunction in males
BE1013958A6 (fr) *	2001-02-05	2003-01-14	Messadek Jallal	Antagonistes glycoproteiques.
WO2000055314A2 (en) *	1999-03-18	2000-09-21	United Therapeutics Corporation	Inhibitors of endothelin-1 synthesis
US6884772B1 (en) *	1999-10-21	2005-04-26	Kao Corporation	Depilatories and agents for external use
JP2001261575A (ja) *	2000-03-13	2001-09-26	General Hospital Corp	血管収縮を調節する方法とその組成物
AU2072002A (en) *	2000-11-28	2002-06-11	Mondobiotech Sa	Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
US20030070674A1 (en) *	2001-10-12	2003-04-17	Bryan Perry	Use of aerosolized compounds in the treatment of exercise induced pulmonary hemorrhage in an equine
BE1015608A6 (fr) *	2003-07-15	2005-06-07	Messadek Jallal	Traitement des arterites.
ES2278314T3 (es) *	2003-04-17	2007-08-01	Jallal Messadek	Formulaciones orales para la liberacion controlada de la betaina.
BE1016128A6 (fr) *	2004-07-22	2006-03-07	Messadek Jallal	Combinaisons therapeutiques
WO2006050581A2 (en) *	2004-11-10	2006-05-18	Jallal Messadek	Betaine as agent against arthropod - or mosquito -borne diseases
US8080549B2 (en) *	2007-01-12	2011-12-20	Concert Pharmaceuticals, Inc.	Endothelin receptor antagonists
WO2008088727A2 (en)	2007-01-12	2008-07-24	Concert Pharmaceuticals, Inc.	Endothelin receptor antagonists
US20090005319A1 (en) *	2007-07-01	2009-01-01	Barone Jr Frank V	Topical compositions for delaying ejaculation and methods of using the same
WO2009033660A2 (en) *	2007-09-11	2009-03-19	Mondobiotech Laboratories Ag	Use of octreotide as a therapeutic agent
WO2009065193A1 (en) *	2007-11-21	2009-05-28	Jallal Messadek	Treatment of aspirin resistance with betaine and/or betaine enriched molasses
BRPI0800596A2 (pt)	2008-01-31	2009-09-22	Univ Minas Gerais	método para a potencialização da função erétil através do uso das composições farmacêuticas de toxina tx2-6 da aranha phoneutria nigriventer
CA2719134C (en)	2008-03-21	2015-06-30	The University Of Chicago	Treatment with opioid antagonists and mtor inhibitors
EP3020715B1 (de) *	2013-07-12	2021-06-16	Sumitomo Chemical Company Limited	Tetrazolinonverbindung und verwendung davon
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5284828A (en)	1990-05-14	1994-02-08	Fujisawa Pharmaceutical Co. Ltd.	Peptide compound and its preparation
EP0569487A1 (de)	1991-01-31	1993-11-18	Abbott Laboratories	Endothelin konvertierende enzyminhibitoren
US5382569A (en)	1991-05-16	1995-01-17	Warner-Lambert Company	Endotherlin antagonists
US5378715A (en)	1992-02-24	1995-01-03	Bristol-Myers Squibb Co.	Sulfonamide endothelin antagonists
US5550110A (en) *	1992-04-22	1996-08-27	Warner-Lambert Company	Endothelin Antagonists II
FI944905A7 (fi) *	1992-04-22	1994-10-19	Warner Lambert Co	Endoteliiniantagonistit II
US5688499A (en)	1996-03-13	1997-11-18	Queen's University At Kingston	Antagonism of endothelin actions

1996
- 1996-03-13 US US08/615,659 patent/US5688499A/en not_active Expired - Fee Related
1997
- 1997-03-13 AT AT97906058T patent/ATE254927T1/de not_active IP Right Cessation
- 1997-03-13 CA CA002248047A patent/CA2248047C/en not_active Expired - Fee Related
- 1997-03-13 JP JP09532139A patent/JP2001500840A/ja not_active Ceased
- 1997-03-13 DE DE69726414T patent/DE69726414D1/de not_active Expired - Lifetime
- 1997-03-13 WO PCT/CA1997/000169 patent/WO1997033608A2/en not_active Ceased
- 1997-03-13 AU AU20885/97A patent/AU723384B2/en not_active Ceased
- 1997-03-13 EP EP97906058A patent/EP0888123B1/de not_active Expired - Lifetime
1998
- 1998-09-14 US US09/152,874 patent/US6410007B1/en not_active Expired - Fee Related
2000
- 2000-07-18 US US09/618,477 patent/US6586391B1/en not_active Expired - Fee Related
2002
- 2002-03-11 US US10/097,206 patent/US20020193307A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO1997033608A3 (en)	1997-11-06
AU2088597A (en)	1997-10-01
EP0888123B1 (de)	2003-11-26
DE69726414D1 (de)	2004-01-08
US6586391B1 (en)	2003-07-01
JP2001500840A (ja)	2001-01-23
CA2248047A1 (en)	1997-09-18
EP0888123A2 (de)	1999-01-07
CA2248047C (en)	2002-10-01
US20020193307A1 (en)	2002-12-19
US6410007B1 (en)	2002-06-25
WO1997033608A2 (en)	1997-09-18
US5688499A (en)	1997-11-18
AU723384B2 (en)	2000-08-24

Legal Events

Date	Code	Title	Description
2004-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE254927T1 (de)	2003-12-15	Antagonisten der endothelinwirkung
BG101607A (en)	1998-02-27	Dihydropyrimdines and uses thereof
DK1135153T3 (da)	2005-08-15	Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
HRP20010119B1 (hr)	2008-05-31	Sprječavanje stvaranja sluzi u dišnim putevima primjenom antagonista egf-r
ATE265209T1 (de)	2004-05-15	Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten
EP1253929A4 (de)	2003-03-05	Verwendung von relaxin zur behandlung von durch gefässverengung bedingte erkrankungen
WO2000012110A3 (en)	2000-08-03	Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
EE9800173A (et)	1998-12-15	Gonadotropiini riliisinghormooni antagonistid
TR200400260T4 (tr)	2004-03-22	Trombin peptid türevleri ile kemik büyümesinin uyarılması
BR0109515A (pt)	2004-08-10	Derivados da apomorfina e métodos para seu uso
BR9910144A (pt)	2002-04-02	Antagonistas de receptores de quimiocinas e seu uso
DE69833748D1 (de)	2006-05-04	Benzocycloheptha-thiophen verbindungen
ATE428427T1 (de)	2009-05-15	Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
HUP9800938A2 (hu)	1999-01-28	NK-1 receptor antagonisták alkalmazása irritációs bélszindróma tüneteinek kezelésére
EA200200207A1 (ru)	2002-08-29	Применение антагонистов cgrp и ингибиторов высвобождения cgrp для устранения приливов в период менопаузы
WO1997010824A8 (en)	1999-08-05	Use of 5ht1b receptor antagonist for the treatment of vascular disease
WO2001022919A3 (en)	2002-07-11	Spiro[bicyclic -azacycloalkyl and -cycloalkyl] derivatives and uses thereof
KR960700696A (ko)	1996-02-24	정맥성 질환 치료에 유용한 5-하이드록시트립타민-2 수용체 길항물질 조성물(5-ht₂receptor antagonist compositions useful in treating venous conditions)
ATE289506T1 (de)	2005-03-15	Hemmung der tnf-aktivität mit zusammensetzungen enthaltend heparin und lösliche tnf rezeptoren
IL148777A (en)	2013-10-31	Mirtazepine oral oral administration unit
LU90506I2 (fr)	2000-03-28	Dorlozamide ou un sel ophtamologiquement acceptable de celui-ci de pr-f-rence l'hydrochlorure de dorzolamide et le timolol ou un sel ophtamologiquement acceptable de celui-ci de pr-f-rence le mal-ate de timolol
BR0000486A (pt)	2001-08-21	Antagonistas do neuropeptìdeo y
ES2181915T3 (es)	2003-03-01	Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones.
ES2070148T3 (es)	1995-06-01	Derivado de la glicerina y utilizacion farmacologica del mismo.
BR9813114A (pt)	2000-08-15	Uso de antagonistas tnf para produzir medicamentos, pacote comercial, e, processo para estabelecer se um paciente que esteja sofrendo de sépsis deva ser tratado com os antagonistas tnf